AbbVie Knocks Back Ablynx's Vobarilizumab In RA
Executive Summary
A major setback for Ablynx as AbbVie decides not to exercise its opt-in for vobarilizumab in rheumatoid arthritis. Though the competitive landscape of biologics targeting IL-6 casts a shadow over its commercial prospects, Ablynx is determined to continue development.
You may also be interested in...
Ablynx's AbbVie-Partnered Lupus Candidate Hits End Of Road
Ablynx's IL-6 inhibitor has reached the end of the road in lupus; failure of the Phase II STEADY trial is unlikely to affect the biotech's acquisition deal with Sanofi but its development partner AbbVie is expected to dump the drug.
Safety Issues Not Dampening AbbVie Optimism For Humira Successors
AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a thromboembolic class effect for JAK inhibitors.
Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.